Science 37 Holdings (Science 37 Holdings) Debt-to-Equity : 0.01 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Debt-to-Equity?

Science 37 Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.53 Mil. Science 37 Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.05 Mil. Science 37 Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $51.74 Mil. Science 37 Holdings's debt to equity for the quarter that ended in Sep. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Science 37 Holdings's Debt-to-Equity or its related term are showing as below:

SNCE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.01 Max: 0.02
Current: 0.01

During the past 3 years, the highest Debt-to-Equity Ratio of Science 37 Holdings was 0.02. The lowest was -0.02. And the median was 0.01.

SNCE's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.49 vs SNCE: 0.01

Science 37 Holdings Debt-to-Equity Historical Data

The historical data trend for Science 37 Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Debt-to-Equity Chart

Science 37 Holdings Annual Data

Trend

Jun20

Jun21

Dec22

Debt-to-Equity

0.01

Science 37 Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial									0.01	0.01	0.02	0.02	0.01

Competitive Comparison of Science 37 Holdings's Debt-to-Equity

For the Health Information Services subindustry, Science 37 Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Science 37 Holdings's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Science 37 Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Science 37 Holdings's Debt-to-Equity falls into.

Science 37 Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Science 37 Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.606	+	0.716)	/	97.386
	=	0.01

Science 37 Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.534	+	0.047)	/	51.744
	=	0.01

Science 37 Holdings (NAS:SNCE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Science 37 Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Science 37 Holdings (Science 37 Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709

Website

https://www.science37.com

Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.

Executives

Troy Bryenton	officer: Chief Technology Officer	800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari	officer: Chief Legal Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von	director	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton	officer: Chief Commercial Officer	800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman	officer: Chief Delivery Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman	director, officer: Chief Executive Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar	officer: Chief Medical Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon	officer: Chief Commercial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B.	director	PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek	officer: Chief Financial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc.	10 percent owner	929 NORTH FRONT STREET, WILMINGTON NC 28401-3331